Document:

EX-10.30

 Exhibit 10.30 

SEPARATION AGREEMENT 
 VAN SMITH
(“Employee”) and FAIRMOUNT SANTROL, INC. with its principal place of business at 8834 Mayfield Road, Chesterland, Ohio 44024, (the “Company”), in exchange for their mutual covenants and obligations set forth herein, hereby agree
as follows: 
  

	 	1.	Separation. Employee’s employment with the Company shall cease effective at the close of business on December 31, 2015 (“Date of Separation”). 

 

	 	2.	Transition Stipend. Employee shall receive a lump sum payment of Two Hundred Ten Thousand Dollars ($210,000.00), minus appropriate withholdings and deductions, including, but not limited to, applicable FICA
deductions and federal, state and city income tax deductions, within fourteen (14) days of the Effective Date of this Agreement, as indicated below. Such amount is being provided by the Company to assist Employee in his transition from
employment with the Company. 

  

	 	3.	Transition Payments—Restrictive Covenants. Employee also shall receive five (5) equal installment payments of Fifty Thousand Dollars ($50,000.00) each, minus appropriate withholdings and deductions,
including, but not limited to, FICA deductions and federal, state and city income tax deductions, payable on the next regular pay days after the following dates: April 1st, July 1st and October 3rd of 2016; and January 6th
and March 31st of 2017. 

 Employee acknowledges that these transition payments represent a new payment arrangement and do
not substitute or replace any other payments to which Employee is entitled. Further, Employee agrees and recognizes that these transition payments are being provided to Employee exclusively in exchange for his covenants and agreements set forth in
Paragraphs Thirteen (13) and Fourteen (14) hereof. Should Employee breach any of his obligations under these Paragraphs, the parties hereto agree that, at the Company’s election, Employee shall repay the Company all of these
installment transition payments received as of the date of the breach and further, shall have no entitlement to any further payments under this Paragraph. In return, Employee, after full repayment is made, shall be relieved of any further
obligations under Paragraphs Thirteen (13) and Fourteen (14) hereof. 
 Should any reviewing Court deem the restrictive covenants
set forth in Paragraphs Thirteen (13) and/or Fourteen (14) void and unenforceable in whole or in part, the Company shall be relieved from any obligation to pay Employee as provided in this Paragraph and Employee shall repay the Company for
any installment transition payments received to date by Employee. 
  

	 	4.	Equity Awards. Employee acknowledges that he has received grants of stock options from Fairmount Santrol Holdings Inc. (f/k/a FMSA Holdings Inc., f/k/a/ FML Holdings, Inc.) (“Holdings”) as summarized in
the table set forth on Exhibit A attached hereto (collectively, the “Stock Options”). The Stock Options were granted pursuant to the terms of one of Holdings’ 2010 Stock Option Plan (the “2010 Plan”) or Holdings’ 2014
Long Term Incentive Plan (the “2014 Plan,” and together with the 2010 Plan, the “Equity Plans”) and an applicable stock option award agreement (each, an “Option Agreement”). Under the terms of the applicable Equity Plan
and/or the applicable Option Agreement, Employee may exercise any portion of the Stock Options that is vested and exercisable as of the Date of Separation until the earlier of (i) the end of the three-month period following the Date of
Separation or (ii) the Stock Option’s expiration date (as provided in the applicable Option Agreement) (the “Exercise Period”). Any Stock Option that is not exercised by the end of the Exercise Period shall be immediately
cancelled and forfeited as of the end of the Exercise Period. Any portion of a Stock Option that is not vested or exercisable as of the Date of Separation shall be immediately cancelled and forfeited as of the Date of Separation. 

Employee further acknowledges that he has received grants of restricted stock units from Holdings pursuant to the terms of the 2014 Plan and
the applicable award agreement (the “RSU Agreement”), as set forth on Exhibit A attached hereto (the “RSUs”). Under the terms of the 2014 Plan and the RSU Agreement, any RSUs that are unvested as of the Date of Separation will
immediately terminate as of 

 
the Date of Separation. Employee acknowledges that, as of the Date of Separation, no RSUs will be vested and, accordingly, all RSUs shall immediately terminate on the Date of Separation. 

The Company and Employee further acknowledge and agree that, as of the Date of Separation and thereafter, Employee shall not be considered a
member of the Window Group, as such term is defined in the Company’s Insider Trading Policy. 
  

	 	5.	Benefit Continuation. Employee shall be entitled to continuation of coverage under the Company’s medical plan pursuant to any rights he may have under the federal Consolidated Omnibus Budget Reconciliation
Act, as amended (“COBRA”), part VI of Subtitle B of Title I of the Employee Retirement Income Security Act of 1974 (“ERISA”), as amended; Internal Revenue Code §4980(B)(f). Such continuation shall be afforded up to the
maximum period provided by law so long as Employee timely elects coverage and otherwise complies with conditions of continuation on a timely basis. All Company provided benefits will cease upon the Date of Separation at midnight. Should Employee
timely elect COBRA continuation of the Company’s medical plan, the Company shall pay the premiums for such coverage through and including March 31, 2017; thereafter, Employee shall be responsible for payment for any future COBRA
continuation coverage. 

  

	 	6.	Outplacement Assistance. The Company shall provide Employee executive-level outplacement assistance as it deems appropriate through the Company’s provider, Ratliff & Taylor, through its partnership
with Career Partners International. Employee shall begin such assistance on or before March 31, 2017 and remain actively engaged therein or such assistance shall be forfeited. 

 

	 	7.	Unemployment. Employee shall be entitled to participate in the Unemployment Compensation Fund of the State of Texas pursuant to and in accordance with the laws of the State. The Company shall not contest
Employee’s eligibility to participate in such Unemployment Compensation Fund. 

  

	 	8.	Employee’s Release. In consideration of the promises and agreements set forth herein, Employee does hereby for himself and for his heirs, executors, successors and assigns, release and forever discharge the
Company, its parents, subsidiaries, divisions, and affiliated businesses, direct or indirect, if any, together with its and their respective officers, directors, trustees, shareholders, management, representatives, agents, employees, plan
administrators, successors, assigns, and attorneys, both known and unknown, in both their personal and agency capacities (collectively, the “Company Entities”) of and from any and all claims, demands, damages, actions or causes of action,
suits, claims, complaints, contracts, whether oral or written, express or implied and promises, at law or in equity, of whatsoever kind or nature, including but not limited to any alleged violation of any state or federal anti-discrimination
statutes or regulations, including, but not limited to, Title VII of The Civil Rights Act of 1964 as amended, ERISA, the Americans With Disabilities Act, the Age Discrimination in Employment Act, the Older Workers Benefit Protection Act
(“OWBPA”), breach of any express or implied contract or promise, wrongful discharge, violation of public policy, tort claims, all demands for attorney’s fees, back pay, holiday pay, vacation pay, bonus, group insurance, any claims for
reinstatement, all employee benefits and claims for money, out of pocket expenses, any claims for emotional distress, degradation, and humiliation, that Employee might now have or may subsequently have, whether known or unknown, suspected or
unsuspected, by reason of any matter or thing, arising out of or in any way connected with, directly or indirectly, any acts or omissions of the Company Entities which have occurred prior to and including the date of Employee’s execution of
this Agreement, except those matters specifically set forth herein and except for any pension or 401(K) benefits which may have vested on Employee’s behalf, if any, and any rights to unemployment benefits which Employee may have.

 This release does not apply to Employee’s rights and entitlements in regard to the Option Agreement referenced in
Paragraph 4 hereof, any 401(k) Plan or to his rights and entitlements under this Agreement. Moreover, Employee may file a charge with, testify, assist, or participate in an investigation, hearing or proceeding conducted by the Equal Employment
Opportunity Commission or state civil rights agency as to the employment laws enforced by such agencies; provided, however, that Employee understands and agrees that he is waiving and releasing his rights to monetary damages under such laws by
reason of her agreement to the general release language stated above. 

	 	9.	Older Workers Benefit Protection Act (“OWBPA”). Employee recognizes and understands that, by executing this Agreement, he shall be releasing the Company Entities from any claims that he now has, may
have, or subsequently may have under the Age Discrimination in Employment Act of 1967, 29 U.S.C. §§621, et seq., as amended, by reason of any matter or thing arising out of, or in any way connected with, directly or indirectly, any acts or
omissions which have occurred prior to and including the Effective Date of this Agreement. In other words, Employee will have none of the legal rights against the aforementioned that he would otherwise have under the Age Discrimination in Employment
Act of 1967, 29 U.S.C. §§621, et seq., as amended, by his signing this Agreement. 

  

	 	10.	Consideration Period. The Company hereby notifies Employee of his right to consult with his chosen legal counsel before signing this Agreement. The Company shall afford, and Employee acknowledges receiving, not
fewer than twenty-one (21) calendar days in which to consider this Agreement to ensure that Employee’s execution of this Agreement is knowing and voluntary. In signing below, Employee expressly acknowledges that he has been afforded the
opportunity to take at least twenty-one (21) days to consider this Agreement and that his execution of same is with full knowledge of the consequences thereof and is of his own free will. 

Notwithstanding the fact that the Company has allowed Employee twenty-one (21) days to consider this Agreement, Employee may elect to
execute this Agreement prior to the end of such 21-day period. If Employee elects to execute this Agreement prior to the end of such 21-day period, then by his signature below, Employee represents that his decision to accept this shortening of the
time was knowing and voluntary, and was not induced by fraud, misrepresentation, or any threat to withdraw or alter the benefits provided by the Company herein, or by the Company providing different terms to any similarly-situated employee executing
this Agreement prior to end of such 21-day consideration period. 
  

	 	11.	Revocation Period. Both the Company and Employee agree and recognize that, for a period of seven (7) calendar days following Employee’s execution of this Agreement, Employee may revoke this Agreement by
providing written notice revoking the same, within this seven (7) day period, delivered by hand or by certified mail, addressed to Reggie Stover, Vice President, People and Talent Development, at the Company’s above-indicated address,
delivered or postmarked within such seven (7) day period. In the event Employee so revokes this Agreement, each party will receive only those entitlements and/or benefits that he/it would have received regardless of this Agreement.

  

	 	12.	Nondisclosure. Employee agrees at all times to hold as secret and confidential (unless disclosure is required pursuant to a court order, subpoena in a governmental proceeding, or pursuant to other process or
requirement of law) any and all confidential, proprietary, or trade secret information, knowledge, technical information, business information, developments, know-how and/or confidences of the Company Entities, including, but not limited to, the
Company’s trade secrets, knowledge, data and know-how relating to the development, manufacturing, application, marketing, and sales of the Company’s products, including but not limited to terms: (i) of a business nature, such as, but
not limited to, memoranda, letters, information or materials relating to applications, technical matters, costs, profits, price, markets, sales, or customer or prospective customer lists, information, contacts and relationships, and marketing
concepts, materials techniques and methods; (ii) of a technical nature, such as, but not limited to, plans, processes, tools, mechanisms, compounds, formulae, equations, forms, drawings, prints, manuals, notebooks, reports, sketches, methods,
design specifications, application concepts and specifications, engineering, computer printouts and programs, compositions, inventions, patent applications, machines, and/or research projects; and (iii) pertaining to future business or product
developments and applications by the Company (collectively, the “Confidential Information”). 

 Employee agrees that
Employee will not, without prior written consent from the Company Entities, use for Employee’s own benefit or for the benefit of any other party, divulge or convey, either orally or in written form, any such Confidential Information obtained or
developed by Employee, at any time in the future, until such information becomes general and public knowledge through no fault of Employee. 
  

	 	13.	 Noncompetition. To protect the Company’s goodwill, business interests, and Confidential Information, Employee covenants and agrees that
for a period beginning on the Date of Separation and continuing 

	 	
for fifteen (15) months thereafter (the “Noncompetition Period”), Employee will not, without the prior written consent of the Company, either directly or indirectly, operate,
manage, direct, control, advise, be employed and/or engaged by, perform any consulting services for, invest in, or otherwise become associated with any person, company or other entity anywhere within the United States which is in competition with or
engaged in the same or similar conduct, activities, or business as that conducted by the Company Entities at any time during the Noncompetition Period including, but not limited to, the industrial sand, resin or elastomer coated sand and ceramics
and/or proppant businesses, including, but not limited to with the following competitors: Emerge Energy Services LP (EMES), US Silica Holdings, Inc. (SLCA), Hi-Crush Limited Partners LP (HCLP), Unimin Corporation, Superior Silica Sands, Preferred
Sands, Eagle Materials (EXP), CARBO Ceramics, Inc. (CRR), Momentive and Badger Mining Corporation/Atlas Resin Proppants; provided, however, that this restriction is not designed or intended to prohibit Employee from being engaged in or associated
with a business providing oil field services or constituting an “E&P” (energy & producer) entity provided that such business or entity is not also involved in sand-related and/or frac-related activities and/or business
concerns. Employee agrees that the restriction on Employee’s ability to compete with the Company anywhere in the United States is appropriate because the Company is engaged in business nationwide. Employee further agrees that this restriction
on Employee’s ability to compete with the Company Entities is reasonable and will not cause Employee any undue hardship. 

Employee acknowledges that this covenant not to compete with the Company is ancillary to the otherwise enforceable agreement between Employee
and the Company set forth in this Agreement. 
  

	 	14.	Nonsolicitation/Noninterference. To protect the Company’s goodwill, business interests, and Confidential Information, Employee covenants and agrees that during the Noncompetition Period, Employee will not,
without the prior written consent of the Company, either directly or indirectly, for Employee’s own benefit, or the benefit of any other person, company, or entity which is or is planning to be in competition with or engaged in the same or
similar conduct, activities, or business as that conducted by the Company Entities at any time during the Noncompetition Period: 

  

	 	a.	solicit, contact, call on, or accept business of the same or similar type being carried on by the Company from any customer and/or prospect of the Company Entities which was a customer or prospective customer of the
Company Entities at any time during Employee’s employment with the Company. Employee acknowledges that this covenant not to solicit these customers and/or prospective customers is ancillary to the otherwise enforceable agreement between
Employee and the Company set forth in this Agreement. 

  

	 	b.	solicit, attempt to hire, employ, or otherwise engage as an employee, independent contractor, or otherwise, any person who is or was an employee, is or was engaged by the Company Entities as a contractor or otherwise
during Employee’s employment with the Company, interfere with the Company’s relationship with such a person, or in any manner induce or attempt to induce such a person to terminate or alter his or her employment or engagement with any of
the Company Entities. 

  

	 	c.	solicit or induce, attempt to solicit or induce, or aid or assist in the solicitation or inducement of any supplier, vendor, or other business contact of the Company Entities for the purpose of having such person,
company, or entity terminate or otherwise change his/her/its business relationship with such Company Entities. Employee understands that Employee may not so interfere with the actual or prospective business relationships of the Company Entities
during the Noncompetition Period. 

  

	 	d.	disparage the Company Entities so as to attempt to undermine, interfere with, or interfere with their business relationships. 

  

	 	15.	Return of Property. Within seven (7) days from the Effective Date of this Agreement, Employee shall return all property belonging to the Company, including, but not limited to, all Confidential Information
as referenced in Paragraph Twelve (12) hereof, all keys, business equipment, computer software and/or hardware, technical manuals, and other Company property. 

	 	16.	Covenant Not to Sue/No Further Action. Employee covenants and agrees that he will not bring, commence, institute, maintain, prosecute, or voluntarily aid any action or proceeding or otherwise prosecute or sue any
of the Company Entities above either affirmatively or by way of cross complaint, defense or counterclaims, or in any other manner with respect to the clams herein released. Employee nonetheless may file and/or participate in administrative charges
with the Equal Employment Opportunity Commission and/or any state law counterpart subject to his release of damages stated above. The foregoing sentence shall be construed as a covenant not to sue. This Separation Agreement may be introduced as
evidence at any legal proceeding as a complete defense to any claims ever asserted by Employee against the Company Entities. 

  

	 	17.	Nondisclosure of Agreement. Employee and his heirs, executors, successors, assigns, and representatives, shall hold the fact and terms of this Agreement in strict confidence and shall not communicate, reveal, or
disclose the terms of this Agreement to any other persons except to Employee’s immediate family, to legal counsel, and to tax consultants, all of whom shall be instructed by Employee similarly to hold the fact and terms of this Agreement in the
strictest confidence, and as required by law. 

  

	 	18.	Warrants. Employee warrants and represents that, prior to and including the date of Employee’s execution of this Agreement, no claim, demand, cause of action, or obligation which is subject to this Agreement
has been assigned or transferred to any other person or entity, and no other person or entity has or has had any interest in said claims, demands, causes of action, or obligations, and that Employee has the sole right to execute this Agreement.

  

	 	19.	Voluntary Agreement. Employee acknowledges and agrees that his election to execute this Agreement is entirely voluntary, and hereby acknowledges that he has not been pressured, coerced, or otherwise unduly
influenced by the Company to execute this Agreement. 

  

	 	20.	Modification. This Agreement shall not be amended or modified in any manner except upon written agreement by the parties. Should any paragraph or provision hereof be deemed void and/or unenforceable, it is the
intention of the parties that such paragraph or provision, and all other terms hereof shall be construed as valid and enforceable consistent with applicable law. 

  

	 	21.	Governing Law/Change of Venue. The parties hereto agree and recognize this Agreement shall be governed and interpreted pursuant to the laws of the State of Ohio notwithstanding any law of any other State or
jurisdiction which a party may claim applies. Any dispute involving or relating to this Agreement shall be litigated exclusively in the appropriate State or Federal Court located in Geauga County, Ohio. 

 

	 	22.	Effective Date. This Agreement shall become effective only upon (a) execution of this Agreement by Employee after the expiration of the twenty-one (21) day consideration period described in Paragraph
Ten (10) hereof, unless such consideration period is voluntarily shortened as provided by law; and (b) the expiration of the seven (7) day period for revocation described in Paragraph Eleven (11) hereof without the release
therein being revoked, but only if such execution and expiration of the revocation period both occur on or prior to January 31, 2016. 

  

	 	23.	 Code Section 409A. The parties intend for this Agreement to comply with Section 409A of the Internal Revenue Code of 1986, as amended
(“Section 409A”). Any term used in this Agreement which is defined in Section 409A or the Treasury Regulations thereunder shall have the meaning set forth therein unless otherwise specifically defined herein. The parties agree that
this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A and all related rules and Treasury Regulations thereunder in order to preserve the payments and benefits provided
hereunder without additional cost to either party. If Employee is a “specified employee” of the Company within the meaning of Section 409A, any payments that would otherwise be paid during the six-month period following the Date of
Separation that constitute “deferred compensation” within the meaning of Section 409A of the Code, taking into account all applicable exceptions, will be deferred and paid on the date which is the first payroll date that is at least
six months and one day following the Date of Separation. The Company makes no representation or warranty and shall have no liability to Employee or any other person if any provisions of this

	 	
Agreement are determined to constitute deferred compensation subject to Section 409A but do not satisfy an exemption or exception from, or the conditions of, Section 409A. Each payment
under this Agreement, including each installment of transition payments payable pursuant to Paragraph Three (3) of this Agreement, shall be considered a separate payment and not one of a series of payments for purposes of Section 409A. All
reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of Section 409A, including, where applicable, the requirement that (i) any reimbursement shall be for expenses
incurred during such period of time specified in this Agreement, (ii) the amount of expenses eligible for reimbursement, or in-kind benefits provided, during a calendar year may not affect the expenses eligible for reimbursement, or in-kind
benefits to be provided, in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred and (iv) the right to
reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. 

 NOTICE TO EMPLOYEE: READ BEFORE SIGNING.
THIS DOCUMENT CONTAINS A RELEASE OF ALL CLAIMS PRIOR TO AND INCLUDING THE DATE OF EMPLOYEE’S EXECUTION OF THIS AGREEMENT. 
 IN WITNESS
WHEREOF, Employee and the Company agree as set forth above: 
  

					
	 December 30, 2015
	 	 /s/ Van T. Smith

	Date of Execution by Employee	 	Agreed to and Accepted by Employee
			
	 December 30, 2015
	 	By:	 	 /s/ Brian J. Richardson

	 Date of Execution by Fairmount Santrol
	 		 	Agreed to and Accepted by
		 	Title:	 	 EVP, Chief People OfficerEXHIBIT 10.16

 

CONFIDENTIAL TREATMENT REQUESTED

 

AMENDMENT NO. 5 TO

 

DRUG DISCOVERY COLLABORATION AGREEMENT

 

THIS AMENDMENT NO.5 TO DRUG DISCOVERY COLLABORATION AGREEMENT (“Amendment”), effective February 18, 2016 (the “Amendment Date”), is by and between Array BioPharma Inc., a Delaware corporation (“Array”), and Loxo Oncology, Inc., a Delaware corporation (“Loxo”).

 

WHEREAS, the parties previously entered into that certain Drug Discovery Collaboration Agreement dated as of July 3, 2013, as amended by Amendment No.1 To Drug Discovery Collaboration Agreement dated November 26, 2013, Amendment No.2 To Drug Discovery Collaboration Agreement dated April 10, 2014, Amendment No. 3 To Drug Discovery Collaboration Agreement dated October 13, 2014, and Amendment No.4 To Drug Discovery Collaboration Agreement dated March 31, 2015 (collectively, the “Agreement”) and the parties wish to amend the Agreement in certain respects on the terms and conditions set forth herein.

 

WHEREAS, as of the Amendment Date, Array and Loxo have identified LOXO-101, a Lead Compound directed to Trk, which is currently the subject of clinical testing by Loxo.

 

WHEREAS, the Parties desire to perform additional research under the Discovery Program with respect to Trk to identify one or more Backup Lead Compounds (as defined below) for potential advancement into clinical development.

 

WHEREAS, as of the Amendment Date, Loxo has designated seven (7) Targets for which research activities have been discontinued and has made the Extension Payment.

 

WHEREAS, as of the Amendment Date, the Parties have agreed to add a new Target to Exhibit B.

 

NOW THEREFORE, capitalized terms not defined in this Amendment shall have the meaning ascribed in the Agreement, and the parties hereby agree as follows:

 

1.                                      “Backup Lead Compound” shall mean an Active Compound that meets the definition of Section 1.1(ii) that is selected for clinical development in accordance with Section 2.5.

 

2.                                      Section 2.1 of the Agreement is hereby deleted and the following substituted therefor:

 

Goals.  The goals of the Discovery Program with respect to the Targets and Trk are (i) the discovery and optimization of Clinical Candidates directed to each of the Targets and to Trk, (ii) the identification of one (1) Lead Compound directed to each of the Targets (iii) the identification of one or more Backup Lead Compounds, (iv) chemistry, manufacturing and control activities directed to and manufacture of quantities of the Lead Compounds sufficient to perform a Phase la (i.e. dose escalation) and a Phase lb (i.e. dose level expansion) clinical trial [*], respectively, and (v) the conduct of IND-Enabling Studies on the Trk Lead Compound and one (1) Lead Compound directed to a Target (selected by Loxo), in all cases pursuant to the Discovery Plan; provided, that Array shall not be required to perform GLP toxicology testing on the Trk Lead Compound and a Lead Compound directed to a Target (selected by Loxo) more than once. With respect to Amendment 5 Triage Targets, an additional goal of the Discovery Program is to perform early screening and lead identification to identify any of such Targets that will be the subject of further research to identify Lead Compounds directed thereto, as described above.

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

 

3.                                      Section 2.4 of the Agreement is hereby deleted and the following substituted therefor:

 

Discovery Program Staffing.  During the Discovery Program and subject to Loxo funding such FTE’s pursuant to Section 5.1, Array shall devote that number of FTE’s to the conduct of the Discovery Program specified in the Discovery Plan. The Discovery Plan shall specify [*] Array FTEs at any time during the Discovery Program Term; provided, however, that during the period beginning on the Amendment Date and ending on [*], the Discovery Plan shall specify an additional [*] FTEs (i.e., for a total of [*] FTEs). Thereafter, Loxo shall have the right, upon [*] months written notice to Array, to increase the number of Array FTEs to be used under the Discovery Program by [*]FTEs (i.e., for a total of up to [*] FTEs). If Loxo exercises such right, then Loxo shall also have the right, upon [*] months written notice to Array, to decrease the number of Array FTEs to be used under the Discovery Program; provided that the Discovery Plan shall specify no fewer than [*] Array FTEs at any time during the Discovery Program Term.

 

4.                                      Section 2.5 is hereby deleted and the following substituted therefor:

 

Selection of Lead Compound or Backup Lead Compound.  Based upon the Clinical Candidate Criteria and the results of the Discovery Program, during the Discovery Program Term the JRC may designate a Clinical Candidate for selection by Loxo as a Lead Compound or Backup Lead Compound. If the JRC determines that a particular Active Compound does not strictly meet the Clinical Candidate Criteria, but should be considered as a potential Lead Compound or Backup Lead Compound, then the JRC may select such Active Compound as a Lead Compound or Backup Lead Compound. Upon approval by Loxo, the Active Compound or Clinical Candidate so designated by the JRC shall be deemed the Lead Compound or Backup Lead Compound, as applicable. Loxo may approve, or withhold its approval of, the designation of any Active Compound as the Lead Compound or Backup Lead Compound in Loxo’s sole discretion, whether or not such Active Compound meets the Clinical Candidate Criteria, and an Active Compound shall not be deemed the Lead Compound or the Backup Lead Compound unless so approved by Loxo. Any Active Compound with respect to which Array (pursuant to the Discovery Plan or with JRC approval) or Loxo initiates IND-Enabling Studies shall be deemed a Lead Compound or Backup Lead Compound, whether or not so designated.

 

5.                                      Section 2.6 of the Agreement is hereby deleted and the following substituted therefor:

 

Term of Discovery Program. The Discovery Program Term shall commence on the Effective Date and shall end on September 30, 2017. Loxo may extend the Discovery Program Term for up to one (1) additional one (1) year renewal period by providing written notice to Array at least three (3) months before the end of the initial Discovery Program Term.

 

6.                                      The list of Targets on Exhibit B is hereby deleted and the attached Exhibit B substituted therefor. Each of the other Targets previously listed on Exhibit B have ceased to be Targets under the Agreement, either as of the date on which Loxo designated such Target for discontinuation or, if not so designated, as of the Amendment Date.

 

7.                                      Section 2.10 is hereby deleted in its entirety and the following substituted therefor:

 

2.10.1 Triage Targets.  With respect to at least one (1) of Targets 3, 4, or 5 from Exhibit B (the “Amendment 5 Triage Targets”), Loxo shall, on or before June 30, 2016, either (i) designate in writing such Amendment 5 Triage Target(s) as an Identified Target for discontinuation followed by substitution pursuant to the procedure set forth in Section 2.10.2 below (it being understood that (a) substitutes may be identified in the discontinuation notice or a subsequent notice, which subsequent notice may be delivered at any time on or before the date that is six (6) months before the end of the

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

 

Discovery Program Term and (b) following such discontinuation and substitution, six (6) Targets shall continue to be listed in Exhibit B), or (ii) notify Array in writing that such Loxo wishes the right to file non-provisional patent applications or publish

 

Collaboration Know-How with respect to such Amendment 5 Triage Target(s) pursuant to Section 2.10.3 below; in either case, such Amendment 5 Triage Target shall cease to be an Amendment 5 Triage Target (but, in the case of (ii) above, shall remain a Target under this Agreement).

 

2.10.2 Target Substitution.  On or before the date that is six (6) months before the end of the Discovery Program Term, but in no case more than two times in any one calendar year, Loxo may determine that research activities with respect to any one of the Amendment 5 Triage Targets should be discontinued (for example, and without limitation, because an Amendment 5 Triage Target has not yielded sufficient progress, or scientific literature suggests such Amendment 5 Triage Target is intractable or is not therapeutically relevant or for safety issues) and want to replace such Amendment 5 Triage Target with a substitute. Upon such designation, such discontinued Target shall cease to be a Target under this Agreement, and Exhibit B shall be deemed to be updated accordingly. Upon such determination by Loxo, Loxo shall provide written notice to Array of the Amendment 5 Triage Target that Loxo desires to remove from Exhibit B (each such Target, an “Identified Target”) and will include in such notification up to three (3) suggested substitutes for each such Identified Target. After receipt of such notice, Array will promptly inform Loxo whether, as of the date of such written notice, the addition of such suggested substitute target would not: (i) violate any agreement that Array has with a Third Party; (ii) add a target that is the subject of Array’s own active and ongoing research (with existing commitment and expenditure of resources for such target), was the subject of previous significant research at Array, or is the subject of drugs in Array’s clinical development pipeline or marketed product portfolio or is the subject of drugs that Array has the right to combine with drugs in its proprietary development pipeline; or (iii) add a target that Array is engaged in active, ongoing substantial negotiations (i.e., has agreed a term sheet containing material business terms) with a Third Party with respect to such target. If none of (i), (ii) or (iii) apply to any given suggested substitute target, such target shall be deemed an “Available Target”. Loxo may select the suggested substitutes for an identified Target from, among others, the potential substitutes listed on Exhibit C hereto. As of the Amendment Date, none of (i), (ii) or (iii) apply to any of the potential substitute targets listed on Exhibit C. Six months after the Amendment Date, Loxo shall eliminate at least three (3) potential substitute targets listed on Exhibit C. Twelve (12) months after the Amendment 5 Date, none of the current targets on Exhibit C will remain on Exhibit C. For clarity, a maximum of six (6) total targets can be maintained on Exhibit C until the six (6) month anniversary of the Amendment Date; and a maximum of three (3) total targets can be maintained on Exhibit C during the period between the six (6) month and the twelve (12) month anniversary of the Amendment Date.

 

Array may also suggest Available Targets to Loxo by providing written notice to Loxo. Upon submission by either Party of an Available Target, the Parties agree to perform a feasibility assessment regarding the Available Target(s) to assess the merits of adding such Target to the Discovery Plan. This feasibility assessment shall be concluded within ninety (90) days for all Available Targets identified in Loxo’s or Array’s notice (“Evaluation Period”). Following completion of such assessment the parties may by mutual agreement decide to replace any Identified Target with the applicable Available Target, provided that Loxo shall have a one-time right to override Array’s refusal to replace one Identified Target with an Available Target upon written notice to Array. Upon replacement of an Identified Target with an Available Target pursuant to the foregoing sentence, such Identified Target shall cease

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

 

to be a Target, the selected Available Target shall deemed a Target for purposes of this Agreement, and Exhibit B shall be deemed to be updated accordingly. An Available Target that becomes a Target shall not be subject to substitution for the term of this Agreement. If a suggested substitute target is not included in Exhibit B, then the fact that Loxo or Array proposed such target or is otherwise interested in such target (or molecules directed to such target), shall be Confidential Information of the Party proposing such target. Without limiting Section 4.3 of the Agreement, each Party agrees not to conduct (or commit to conduct) any activity, whether alone or with any Affiliate or Third Party, with respect to any target proposed by the other Party during the Evaluation Period other than for the purpose of assessing its chemical feasibility. In addition, each Party, when proposing a target to the other Party under this Section 2.10.2, shall not disclose to such other Party any Confidential Information regarding such target without such other Party’s prior consent.

 

2.10.3 Patent Matters.  On or before the date that is six (6) months before the end of the Discovery Program Term or any applicable renewal period, Loxo shall (i) only have the right, at its discretion, to file provisional patent applications covering the applicable Active Compounds to the Amendment 5 Triage Targets and will not convert such provisional patent applications to a non-provisional patent application or otherwise prosecute any non-provisional patent application covering such Active Compounds and (ii) not publish any Collaboration Know-How with respect to activities directed to an Amendment 5 Triage Target. If Loxo wishes to (y) file a non-provisional patent application covering the applicable Active Compounds to a particular Amendment 5 Triage Target (whether by de novo filing of a non-provisional patent application covering such Active Compounds or by converting a provisional patent application covering such Active Compounds to a non-provisional patent application) or (z) publish any Collaboration Know-How with respect to activities directed to a particular Amendment 5 Triage Target, Loxo shall provide written notice to Array of its intent to do so. Upon receipt of such notice, such Target shall remain on Exhibit B, but it shall no longer be deemed an Amendment 5 Triage Target, and Sections 2.10.1 and 2.10.2 and the first sentence of this paragraph shall no longer apply to such Target. For clarity, Loxo shall not be restricted from filing patent applications, whether provisional or non- provisional, with respect to Active Compounds to Targets other than Amendment 5 Triage Targets.

 

8.                                      The first paragraph of Section 4.3 is hereby amended and the following added at the end thereof:

 

In addition, except to the extent required for Array to fulfill its obligations under this Agreement, with respect to any Target added to Exhibit B after the Amendment Date, for as long as Loxo (or a sublicensee or other Third Party on Loxo’s behalf) (a) has an active research and/or development program for such Target, where such program could result in Array accruing milestone payments and royalties; or (b) is commercializing a Product for such Target, Array shall not conduct, participate in, license or fund, directly or indirectly, alone or with any Affiliate or Third Party, discovery research with respect to a product comprising a small molecule that, as a primary mechanism of action for therapeutic or prophylactic effect, binds to and modulates the activity of such Target.

 

9.                                      Section 5.2.1 of the Agreement is hereby amended by deleting the last sentence thereof and substituting the following therefor:

 

For purposes of this Section 5.2.1, the “Array FTE Rate” shall be equal to [*] per FTE per year.

 

10.                               Within ten (10) days of the Amendment Date, Loxo shall pay to Array the sum of [*], which amount is non-refundable and non-creditable against any other payment due under the Agreement.

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

 

11.                               The first two sentences of Section 5.3.1 of the Agreement are hereby replaced with the following:

 

5.3.1 Target Milestones. With respect to Lead Compounds directed to a Target, Loxo shall pay Array the following payments on the first achievement by Loxo or an Affiliate or a sublicensee of Loxo of the following milestone events, with such payments due within thirty (30) days after applicable event occurs. Additionally, with respect to Backup Lead Compounds directed to Trk, Loxo shall pay Array the following payments on the first achievement by Loxo or an Affiliate or a sublicensee of Loxo of the milestone events 1 and 2, with such payments due within thirty (30) days after applicable event occurs. Each payment shall be due only once for each Lead Compound directed to a Target or Backup Lead Compound directed to Trk:

 

12.                               Section 5.3.2 of the Agreement is hereby amended by deleting the last sentence of the introductory paragraph thereof and substituting the following therefor:

 

Each payment shall be due only once for LOXO-101 and each Backup Lead Compound directed to Trk:

 

13.                               The Parties acknowledge that, at the request of Loxo, Array devoted [*] FTEs to the Discovery Program during the month of January 2016 and has devoted [*] FTEs to the Discovery Program during the month of February 2016. Loxo shall pay Array for such FTEs at the rate of [*] per FTE per year.

 

14.                               Miscellaneous.

 

This Amendment shall be effective for all purposes as of the Amendment Date. Except as expressly modified herein, the Agreement shall continue to remain in full force and effect in accordance with its terms. This Amendment may be executed in counterparts, each of which shall be deemed to be an original and together shall be deemed to be one and the same document.

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement to be effective as of the date first above written.

 

	
LOXO   ONCOLOGY, INC.
    	
ARRAY   BIOPHARMA, INC.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
/s/   Joshua Bilenker
    	
 
    	
By: 
    	
/s/ John Moore
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Name:
    	
Joshua   Bilenker
    	
 
    	
Name: 
    	
John R. Moore
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Title:
    	
CEO
    	
 
    	
Title: 
    	
Vice President and   General Counsel
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Date:
    	
2/18/2016
    	
 
    	
Date: 
    	
2/18/2016
    

 

 

CONFIDENTIAL TREATMENT REQUESTED

 

EXHIBIT B

 

Targets

 

1.                                      The protein family commonly known as[*], identified with the following SwissProt entries:

 

a)                                     [*]

 

b)                                     [*]

 

c)                                      [*]

 

d)                                     [*]

 

2.                                      The protein commonly known as [*], identified with the following SwissProt entry:  [*]

 

3.                                      The protein family commonly known as [*], identified with the following SwissProt entries:

 

a)                                     [*]

 

b)                                     [*]

 

4.                                      The protein commonly known as [*], identified with the following SwissProt entry:
 [*], and the protein commonly known as [*], identified with the following SwissProt entry:

 

[*]

 

5.                                      The protein commonly known as [*], identified with the following SwissProt entry:
 [*]

 

6.                                      The protein commonly known as [*], identified with the following SwissProt entry:
 [*]

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

 

CONFIDENTIAL TREATMENT REQUESTED

 

EXHIBIT C

 

Potential Substitutes for Identified Targets

 

1.                                 The protein commonly known as [*], identified with the following SwissProt entry:
 [*]

 

2.                                 The protein commonly known as [*], identified with the following SwissProt entry:
 [*]

 

3.                                      The protein commonly known as [*], identified with the following SwissProt entry:
 [*]

 

4.                                 The protein commonly known as [*], identified with the following SwissProt entry:
 [*]

 

5.                                 The protein commonly known as [*], identified with the following SwissProt entry:
 [*]

 

6.                                 The protein commonly known as [*], identified with the following SwissProt entry:
 [*]

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00255-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00255-of-00352.parquet"}]]